Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 15.93
-0.38 (-2.33%)
Sep 2, 2026, 3:00 PM CST
SHA:688670 Revenue
Jiangsu Gdk Biological Technology had revenue of 12.12K CNY in the quarter ending June 30, 2026, a decrease of -79.94%. This brings the company's revenue in the last twelve months to 110.27M, up 36.07% year-over-year. In the year 2025, Jiangsu Gdk Biological Technology had annual revenue of 112.88M with 39.70% growth.
Revenue (ttm)
110.27M
Revenue Growth
+36.07%
P/S Ratio
18.22
Revenue / Employee
282.74K
Employees
390
Market Cap
2.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 112.88M | 32.08M | 39.70% |
| Dec 31, 2024 | 80.80M | -53.79M | -39.96% |
| Dec 31, 2023 | 134.59M | -183.89M | -57.74% |
| Dec 31, 2022 | 318.49M | -73.79M | -18.81% |
| Dec 31, 2021 | 392.27M | -196.83M | -33.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.15B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Guiyang Xintian Pharmaceutical | 723.26M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Tiansheng Pharmaceutical Group | 514.89M |
| Suzhou Fushilai Pharmaceutical | 394.29M |
| Yantai Zhenghai Biotechnology | 336.07M |